

Isabelle LACROIX - Publications 2015-2019

UMR 1027 : Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps

Equipe émergente : Pharmaco-épidémiologie, évaluation de l'utilisation et du risque médicamenteux

Articles dans des revues internationales ou nationales avec comité de lecture ou dans les bases de données internationales

Mise à jour juillet 2019

2019

1. Araujo M, Hurault-Delarue C, Bouilhac C, Petiot D, Benevent J, Vayssière C, Vidal S, Montastruc JL, Damase-Michel C, **Lacroix I**. [Non-steroidal anti-inflammatory drug prescriptions from the 6th month of pregnancy: impact of advice from health authorities](#). *Fundam Clin Pharmacol*. 2019 Mar 8. doi: 10.1111/fcp.12460. [Epub ahead of print]
2. Benevent J, Araujo M, Hurault-Delarue C, Montastruc JL, Sommet A, **Lacroix I**, Damase-Michel C. [Pharmacoepidemiology in pregnancy](#). *Therapie*. 2019 Apr;74(2):289-300. doi: 10.1016/j.therap.2018.11.014.
3. Montastruc JL, Montastruc F, Benevent J, **Lacroix I**, Durrieu G, Du Plantier JM, Bagheri H, Sommet A, Damase-Michel C. [Tintin in the Land of Drugs: A pharmacological, pharmacovigilance approach](#). *Therapie*. 2019 Jun;74(3):445-447. doi: 10.1016/j.therap.2019.01.002.
4. Danet C, Araujo M, Bos-Thompson MA, Portolan G, Gautier S, Vanlemmens L, Bonenfant S, Jonville-Béra AP, Cottin J, Vial T, Bavoux F, Montastruc JL, Damase-Michel C, Benevent J, Bourgeois-Mondon I, **Lacroix I**. [Pregnancy outcomes in women exposed to cancer chemotherapy](#). *Pharmacoepidemiol Drug Saf*. 2018 Dec;27(12):1302-1308. doi: 10.1002/pds.4689.
5. Benevent J, Hurault-Delarue C, Araujo M, Montastruc F, Montastruc JL, **Lacroix I**, Damase-Michel C. [Higher intake of medications for digestive disorders in children prenatally exposed to drugs with atropinic properties](#). *Fundam Clin Pharmacol*. 2019 Jun;33(3):314-326. doi: 10.1111/fcp.12428.
6. Benevent J, Hurault-Delarue C, Araujo M, Montastruc JL, **Lacroix I**, Damase-Michel C. [POMME: The New Cohort to Evaluate Long-Term Effects After Prenatal Medicine Exposure](#). *Drug Saf*. 2019 Jan;42(1):45-54. doi: 10.1007/s40264-018-0712-9.

2018

1. Bénard-Larivière A, Pambrun E, Sutter-Dallay AL, Gautier S, Hurault-Delarue C, Damase-Michel C, **Lacroix I**, Bégaud B, Pariente A. [Patterns of antidepressant use during pregnancy: a nationwide population-based cohort study](#). *Br J Clin Pharmacol*. 2018 Aug;84(8):1764-1775. doi: 10.1111/bcp.13608.
2. Foch C, Araujo M, Weckel A, Damase-Michel C, Montastruc JL, Benevent J, Durrieu G, **Lacroix I**. [In utero drug exposure and hearing impairment in 2-year-old children A case-control study using the EFEMERIS database](#). *Int J Pediatr Otorhinolaryngol*. 2018 Oct;113:192-197. doi: 10.1016/j.ijporl.2018.07.035.
3. Hurault-Delarue C, **Lacroix I**, Bénard-Larivière A, Montastruc JL, Pariente A, Damase-Michel C. [Antidepressants during pregnancy: a French drug utilisation study in EFEMERIS cohort](#). *Eur Arch Psychiatry Clin Neurosci*. 2018 May 26. doi: 10.1007/s00406-018-0906-2. [Epub ahead of print]
4. Montastruc F, Bagheri H, **Lacroix I**, Damase-Michel C, Chebane L, Rousseau V, Jouanjus E, Lapeyre-Mestre M, Durrieu G, Montastruc JL. [Adverse Drug Reaction Reports Received Through the Mobile](#)

[App, VigiBIP®: A Comparison with Classical Methods of Reporting.](#) Drug Saf. 2018 May;41(5):511-514. doi: 10.1007/s40264-017-0630-2.

2017

1. Beau AB, Didier A, Hurault-Delarue C, Montastruc JL, **Lacroix I**, Damase-Michel C. [Prescription of asthma medications before and during pregnancy in France: An observational drug study using the EFEMERIS database.](#) J Asthma. 2017 Apr;54(3):258-264. doi: 10.1080/02770903.2016.1214731.
2. Beau AB, Tauber M, Chollet C, Hurault-Delarue C, Bouilhac C, Montastruc JL, **Lacroix I**, Damase-Michel C. [A contemporary description of French newborns' growth using the Efemeris cohort.](#) Arch Pediatr. 2017 May;24(5):424-431. doi: 10.1016/j.arcped.2017.02.023.
3. Hurault-Delarue C, Chouquet C, Savy N, **Lacroix I**, Beau AB, Montastruc JL, Damase-Michel C. [Interest of the trajectory method for the evaluation of outcomes after in utero drug exposure: example of anxiolytics and hypnotics.](#)
4. Salgues M, Damase-Michel C, Montastruc JL, **Lacroix I**. [\[Women's knowledge of folic acid\].](#) Therapie. 2017 Jun;72(3):339-343. doi: 10.1016/j.therap.2016.10.001.

2016

1. Bagheri H, **Lacroix I**, Guitton E, Damase-Michel C, Montastruc JL. [Cyberpharmacovigilance: What is the usefulness of the social networks in pharmacovigilance?](#) Therapie. 2016 Apr;71(2):235-9. doi: 10.1016/j.therap.2015.09.002.
2. Beau AB, Montastruc JL, **Lacroix I**, Montastruc F, Hurault-Delarue C, Damase-Michel C. [Atropinic burden of drugs during pregnancy and psychological development of children: a cohort study in the EFEMERIS database.](#) Br J Clin Pharmacol. 2016 Aug;82(2):478-86. doi: 10.1111/bcp.12978.
3. Hurault-Delarue C, Chouquet C, Savy N, **Lacroix I**, Beau AB, Montastruc JL, Damase-Michel C. [How to take into account exposure to drugs over time in pharmacoepidemiology studies of pregnant women?](#) Pharmacoepidemiol Drug Saf. 2016 Jul;25(7):770-7. doi: 10.1002/pds.4000.
4. Hurault-Delarue C, Damase-Michel C, Finotto L, Guitard C, Vayssière C, Montastruc JL, Montastruc F, **Lacroix I**. [Psychomotor developmental effects of prenatal exposure to psychotropic drugs: a study in EFEMERIS database.](#) Fundam Clin Pharmacol. 2016 Oct;30(5):476-82. doi: 10.1111/fcp.12209.
5. **Lacroix I**, Beau AB, Hurault-Delarue C, Bouilhac C, Petiot D, Vayssière C, Vidal S, Montastruc JL, Damase-Michel C. [First epidemiological data for venotonics in pregnancy from the EFEMERIS database.](#) Phlebology. 2016 Jun;31(5):344-8. doi: 10.1177/0268355515589679.
6. Montastruc JL, Bondon-Guitton E, Abadie D, **Lacroix I**, Berreni A, Pugnet G, Durrieu G, Sailler L, Giroud JP, Damase-Michel C, Montastruc F. [Pharmacovigilance, risks and adverse effects of self-medication.](#) Therapie. 2016 Apr;71(2):257-62. doi: 10.1016/j.therap.2016.02.012. [Risk of infections during the first year of life after in utero exposure to drugs acting on immunity: A population-based cohort study.](#) Pharmacol Res. 2016 Nov;113(Pt A):557-562. doi: 10.1016/j.phrs.2016.09.028.
7. Palosse-Cantaloube L, Hurault-Delarue C, Beau AB, Montastruc JL, **Lacroix I**, Damase-Michel C. [Risk of infections during the first year of life after in utero exposure to drugs acting on immunity: A population-based cohort study.](#) Pharmacol Res. 2016 Nov;113(Pt A):557-562. doi: 10.1016/j.phrs.2016.09.028.
8. Villeneuve C, Laroche ML, Essig M, Merville P, Kamar N, Coubret A, **Lacroix I**, Bouchet S, Fruit D, Marquet P, Rousseau A; EPIGREN study group. [Evolution and Determinants of Health-Related Quality-of-Life in Kidney Transplant Patients Over the First 3 Years After Transplantation.](#) Transplantation. 2016 Mar;100(3):640-7. doi: 10.1097/TP.0000000000000846.

2015

1. Abadie D, Hurault-Delarue C, Damase-Michel C, Montastruc JL, **Lacroix I**. [Medication exposure and spontaneous abortion: a case-control study using a French medical database](#). Clin Exp Obstet Gynecol. 2015;42(4):431-6.
2. Palosse-Cantaloube L, **Lacroix I**, Rousseau V, Bagheri H, Montastruc JL, Damase-Michel C. [Analysis of chats on French internet forums about drugs and pregnancy](#). Pharmacoepidemiol Drug Saf. 2014 Dec;23(12):1330-3. doi: 10.1002/pds.3709.